Phase 3
Completed N=248
Long-Term Study of MP-214 in Patients With Schizophrenia
Source: ClinicalTrials.gov NCT01626872 ↗Enrolled (actual)
248
Serious AEs
24.6%
Results posted
Apr 2021
Primary outcomePrimary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 67; 92; 50 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events as a Measure of Safety and Tolerability |
67; 92; 50 | — |
Eligibility Criteria
Inclusion Criteria
- Written informed consent obtained from the patient before the completion of Study A002-A4
- Patients who have completed the A002-A4 study
Exclusion Criteria
- Patients who are experiencing ongoing, uncontrolled, clinically significant adverse events (AEs), as judged by the investigator (or subinvestigator)
The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Data sourced from ClinicalTrials.gov (NCT01626872). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.